Regulatory & Political: The Fate of 7 Popular Peptides\nAll eyes in the industry are on the FDA’s Pharmacy Compounding Advisory Committee (PCAC), which is scheduled to meet July 23-24, 2026. The panel will decide whether to ease restrictions on seven peptides—including BPC-157, Semax, TB-500, Epitalon, Emideltide, KPV, and MOTs-C—allowing them to be legally prepared by 503A compounding pharmacies. These substances were previously moved to the Category 2 restricted "do not compound" list in 2023.\n\nThe meeting has sparked significant political and internal friction. HHS Secretary Robert F. Kennedy Jr. has been publicly supportive of expanding access to these therapeutics. However, reports indicate that FDA career scientists have recommended against clearing these peptides, citing a lack of robust human clinical evidence for safety and efficacy. Furthermore, concerns have been raised regarding the panel's composition, with internal FDA flags suggesting potential conflicts of interest among new committee members who have ties to the peptide industry.\n\n### Market Watch & Legal: GLP-1 Compounding Workarounds and "RUO" Scrutiny\nMeanwhile, compounding pharmacies continue to navigate the post-shortage regulatory landscape for GLP-1 medications. A secret shopper study published July 17, 2026, in JAMA Health Forum revealed that over half of surveyed weight-loss clinics and medical spas are circumventing the FDA's ban on copying approved GLP-1s (which took effect after semaglutide and tirzepatide shortages resolved). They are doing so by having compounders add supplemental ingredients, most commonly B vitamins or glycine, to create "unique" formulations. Researchers noted that this raises ongoing oversight questions, especially as some of the supplying 503A pharmacies had previous FDA warning letters or state board disciplinary actions.\n\nSimultaneously, mainstream media and legal experts are heavily scrutinizing the "Research Use Only" (RUO) gray market. Legal scholars have publicly reiterated that merely labeling a product "for research use only" does not provide legal immunity if the vendor's website or marketing implies the chemicals are intended for human use or wellness benefits.\n\n### Takeaway for RP Wellness\nThis is a highly volatile week for the peptide supply chain. The outcome of the July 23-24 PCAC meeting could either legitimize several popular peptides for clinical compounding or firmly cement their restricted status. In either scenario, regulatory attention on the peptide gray market is currently at a peak. RP Wellness must maintain absolute strictness in its compliance posture: ensure zero health, medical, or human-use claims are made on storefronts or social media channels, and rigorously enforce B2B verification to substantiate the legitimate "Research Use Only" status of your catalog.